跳至主要内容
临床试验/JPRN-UMIN000005995
JPRN-UMIN000005995已完成未知

Prospective study of efficacy and safety of transcatheter arterial chemoembolization (TACE) with miriplatin for hepatocellular carcinoma. - Prospective study of TACE with miriplatin for hepatocellular carcinoma.

Kyoto Prefectural University of Medicine0 个研究点目标入组 200 人开始时间: 2011年7月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1) Refractory pleural effusion or ascites 2) Encephalopathy 3) Concurrent disease a) Serious hypertension b) Severe heart disease c) Acute myocardial infarction within 6 months prior to inclusion d) Active double cancer e) Severe mental disorder f) Allergic reaction to iodine contrast material g) Severe drug allergy 4) Intrahepatic or portal-caval shunts 5) Tumor thrombosis in main portal vein or vena cava 6) Pregnant and lactating females; females of childbearing age unless using effective contraception 7) Patients who are concluded to be inappropriate to participate in this study by their physicians

研究者

相似试验